Journal of Basic Research in Medical Sciences
J Basic Res Med Sci
Volume 13, Issue 3 (6-2026)
jbrms 2026, 13(3): 10-18 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
pourrahim A, Kheiry M. The Role of Stem Cells in Cardiac Tissue Repair After Myocardial Infarction: Physiological Mechanisms. jbrms 2026; 13 (3) :10-18
URL: http://jbrms.medilam.ac.ir/article-1-1067-en.html
URL: http://jbrms.medilam.ac.ir/article-1-1067-en.html
Non-Communicable Diseases Research Center, Ilam University of Medical sciences, Ilam, Iran , m.kheiry@yahoo.com
Abstract: (1431 Views)
Introduction: Myocardial infarction induces IRI, leading to cardiomyocyte necrosis, neutrophil-driven inflammation, and fibroblast-mediated fibrosis, culminating in ventricular dysfunction. Stem Cell such as MSCs promote angiogenesis via VEGF/HGF paracrine secretion; CPCs differentiate through Notch/Wnt for tissue replacement; iPSCs enable patient-specific remuscularization with Cx43 integration.
Aim: The purpose of this study is to investigate the role of stem cells in cardiac tissue repair after myocardial infarction via physiological mechanisms.
Discussion: Stem cell–based therapies represent a promising yet evolving approach for cardiac repair following myocardial infarction. Preclinical models consistently demonstrate improvements in angiogenesis, attenuation of fibrosis, and partial restoration of ventricular function; however, these outcomes have not been fully replicated in clinical trials.
Conclusion: This review synthesizes mechanisms for advancing clinical translation. the future of cardiac regenerative medicine lies in the integration of mechanistic insights with bioengineering and molecular innovation.
Aim: The purpose of this study is to investigate the role of stem cells in cardiac tissue repair after myocardial infarction via physiological mechanisms.
Discussion: Stem cell–based therapies represent a promising yet evolving approach for cardiac repair following myocardial infarction. Preclinical models consistently demonstrate improvements in angiogenesis, attenuation of fibrosis, and partial restoration of ventricular function; however, these outcomes have not been fully replicated in clinical trials.
Conclusion: This review synthesizes mechanisms for advancing clinical translation. the future of cardiac regenerative medicine lies in the integration of mechanistic insights with bioengineering and molecular innovation.
Type of Study: Narrative review |
Subject:
Physiology
Received: 2025/12/24 | Accepted: 2026/04/6 | Published: 2026/06/16
Received: 2025/12/24 | Accepted: 2026/04/6 | Published: 2026/06/16
References
1. Xu Y, Wu S, Zhang L, Zhang M, Jiang Y. Cell death forms in myocardial ischemia-reperfusion injury and their potential clinical applications. Molecular and Cellular Biochemistry.2025:1-15. [DOI:10.1007/s11010-025-05440-7]
2. Gao J, Li L, Zhai S, Dong Y, Zhang Z, Lin D, et al. Exercise training for myocardial ischemia reperfusion injury: Mechanism and clinical practice. International Journal of Molecular Medicine. 2025;56(5):191. [DOI:10.3892/ijmm.2025.5632.]
3. Guo M, Watanabe T, Shinoka T. Injectable Stem Cell-Based Therapies for Myocardial Regeneration: A Review of the Literature. Journal of Functional Biomaterials. 2025;16(5):152. [DOI:10.3390/jfb16050152.]
4. Ali SA, Mahmood Z, Mubarak Z, Asad M, Chaudhri MTS, Bilal L, et al. Assessing the Potential Benefits of Stem Cell Therapy in Cardiac Regeneration for Patients With Ischemic Heart Disease. Cureus. 2025;17(1). [DOI:10.7759/cureus.76770.]
5. Inouye K, White G, Khan S, Luba J, Benharash P, Thankam FG. Heart-derived endogenous stem cells. Molecular Biology Reports. 2025;52(1):1-13. [DOI:10.1007/s11033-025-11001-4.]
6. Cambria E, Steiger J, Günter J, Bopp A, Wolint P, Hoerstrup SP, et al. Cardiac regenerative medicine: the potential of a new generation of stem cells. Transfusion Medicine and Hemotherapy. 2016;43(4):275-81. [DOI:10.1159/000448179.]
7. Moraddahande FM, Meybodi SME, Matin M, Soleimani N, Ghasemzadeh N, Firoozabadi AD. Current status and new horizons in stem cell therapy in cardiovascular regenerative medicine (CaVaReM): an update. European Journal of Medical Research. 2025;30(1):837. [DOI:10.1186/s40001-025-03018-z.]
8. Noorabadi P, Shahabi Rabori V, Jamali S, Jafari N, Saberiyan M. An overview on cardiac regeneration revolution: exploring the promise of stem cell therapies. Molecular Biology Reports. 2025;52(1):511. [DOI:10.1007/s11033-025-10580-6.]
9. Mirotsou M, Jayawardena TM, Schmeckpeper J, Gnecchi M, Dzau VJ. Paracrine mechanisms of stem cell reparative and regenerative actions in the heart. Journal of molecular and cellular cardiology. 2011;50(2):280-9. [DOI:10.1016/j.yjmcc.2010.08.005.]
10. Broughton KM, Wang BJ, Firouzi F, Khalafalla F, Dimmeler S, Fernandez-Aviles F, et al. Mechanisms of cardiac repair and regeneration. Circulation research. 2018;122(8):1151-63. [DOI:10.1161/CIRCRESAHA.117.312586.]
11. Collet BC, Davis DR. Mechanisms of cardiac repair in cell therapy. Heart, Lung and Circulation. 2023;32(7):825-35. [DOI:10.1016/j.hlc.2023.01.019.]
12. Terashvili M, Bosnjak ZJ. Stem cell therapies in cardiovascular disease. Journal of cardiothoracic and vascular anesthesia. 2019;33(1):209-22. [DOI:10.1053/j.jvca.2018.04.048.]
13. He L, Nguyen NB, Ardehali R, Zhou B. Heart regeneration by endogenous stem cells and cardiomyocyte proliferation: controversy, fallacy, and progress. Circulation. 2020;142(3):275-91. [DOI:10.1161/CIRCULATIONAHA.119.045566.]
14. Katarzyna R. Adult stem cell therapy for cardiac repair in patients after acute myocardial infarction leading to ischemic heart failure: an overview of evidence from the recent clinical trials. Current cardiology reviews. 2017;13(3):223-31. [DOI:10.2174/1573403X13666170502103833.]
15. Sun Q, Zhang Z, Sun Z. The potential and challenges of using stem cells for cardiovascular repair and regeneration. Genes & diseases. 2014;1(1):113-9. https://doi.org/ 10.1016/j.gendis.2014.07.003. [DOI:10.1016/j.gendis.2014.07.003.]
16. Tompkins BA, Balkan W, Winkler J, Gyöngyösi M, Goliasch G, Fernández-Avilés F, et al. Preclinical studies of stem cell therapy for heart disease. Circulation research. 2018;122(7):1006-20. https://doi.org/ 10.1161/CIRCRESAHA.117.312486. [DOI:10.1161/CIRCRESAHA.117.312486.]
17. Yu Y, Tham SK, Roslan FF, Shaharuddin B, Yong YK, Guo Z, et al. Large animal models for cardiac remuscularization studies: a methodological review. Frontiers in Cardiovascular Medicine. 2023;10:1011880. https://doi.org/ 10.3389/fcvm.2023.1011880. [DOI:10.3389/fcvm.2023.1011880.]
18. Duran JM, Makarewich CA, Sharp TE, Starosta T, Zhu F, Hoffman NE, et al. Bone-derived stem cells repair the heart after myocardial infarction through transdifferentiation and paracrine signaling mechanisms. Circulation research. 2013;113(5):539-52. https://doi.org/ 10.1161/CIRCRESAHA.113.301202. [DOI:10.1161/CIRCRESAHA.113.301202.]
19. Wan J, Lin S, Yu Z, Song Z, Lin X, Xu R, et al. Protective Effects of MicroRNA‐200b‐3p Encapsulated by Mesenchymal Stem Cells–Secreted Extracellular Vesicles in Myocardial Infarction Via Regulating BCL2L11. Journal of the American Heart Association. 2022;11(12):e024330. https://doi.org/ 10.1161/JAHA.121.024330. [DOI:10.1161/JAHA.121.024330.]
20. Yue R, Lu S, Luo Y, Zeng J, Liang H, Qin D, et al. Mesenchymal stem cell-derived exosomal microRNA-182-5p alleviates myocardial ischemia/reperfusion injury by targeting GSDMD in mice. Cell death discovery. 2022;8(1):202. https://doi.org/ 10.1038/s41420-022-00909-6 [DOI:10.1038/s41420-022-00909-6]
21. Shao L, Zhang Y, Lan B, Wang J, Zhang Z, Zhang L, et al. MiRNA‐sequence indicates that mesenchymal stem cells and exosomes have similar mechanism to enhance cardiac repair. BioMed research international. 2017;2017(1):4150705. https://doi.org/ 10.1155/2017/4150705. [DOI:10.1155/2017/4150705.]
22. Wen Z, Huang W, Feng Y, Cai W, Wang Y, Wang X, et al. MicroRNA-377 regulates mesenchymal stem cell-induced angiogenesis in ischemic hearts by targeting VEGF. PLoS One. 2014;9(9):e104666. https://doi.org/ 10.1371/journal.pone.0104666. [DOI:10.1371/journal.pone.0104666.]
23. Maries L, Marian C, Sosdean R, Goanta F, Sirbu IO, Anghel A. MicroRNAs—The Heart of Post-Myocardial Infarction Remodeling. Diagnostics. 2021;11(9):1675. https://doi.org/ 10.3390/diagnostics11091675. [DOI:10.3390/diagnostics11091675.]
24. Wang J, Huang W, Xu R, Nie Y, Cao X, Meng J, et al. Micro RNA‐24 regulates cardiac fibrosis after myocardial infarction. Journal of cellular and molecular medicine. 2012;16(9):2150-60. https://doi.org/ 10.1111/j.1582-4934.2012.01523.x [DOI:10.1111/j.1582-4934.2012.01523.x]
25. Li L, Bounds KR, Chatterjee P, Gupta S. Micro RNA‐130a, a potential antifibrotic target in cardiac fibrosis. Journal of the American Heart Association. 2017;6(11):e006763. https://doi.org/ 10.1161/JAHA.117.006763 [DOI:10.1161/JAHA.117.006763]
26. Zhou Y, Richards AM, Wang P. MicroRNA-221 is cardioprotective and anti-fibrotic in a rat model of myocardial infarction. Molecular therapy Nucleic acids. 2019;17:185-97. https://doi.org/ 10.1016/j.omtn.2019.05.018 [DOI:10.1016/j.omtn.2019.05.018]
27. Ji X, Wu B, Fan J, Han R, Luo C, Wang T, et al. The anti-fibrotic effects and mechanisms of microRNA-486-5p in pulmonary fibrosis. Scientific reports. 2015;5(1):14131. https://doi.org/ 10.1038/srep14131 [DOI:10.1038/srep14131]
28. Du W, Liang H, Gao X, Li X, Zhang Y, Pan Z, et al. MicroRNA-328, a potential anti-fibrotic target in cardiac interstitial fibrosis. Cellular Physiology and Biochemistry. 2016;39(3):827-36. https://doi.org/ 10.1159/000447793 [DOI:10.1159/000447793]
29. Huang X, Liang X, Han Q, Shen Y, Chen J, Li Z, et al. Pretreatment with growth differentiation factor 15 augments cardioprotection by mesenchymal stem cells in myocardial infarction by improving their survival. Stem Cell Research & Therapy. 2024;15(1):412. https://doi.org/ 10.1186/s13287-024-04030-6 [DOI:10.1186/s13287-024-04030-6]
30. Selvakumar D, Clayton ZE, Prowse A, Dingwall S, Kim SK, Reyes L, et al. Cellular heterogeneity of pluripotent stem cell-derived cardiomyocyte grafts is mechanistically linked to treatable arrhythmias. Nature Cardiovascular Research. 2024;3(2):145-65. https://doi.org/ 10.1038/s44161-023-00419-3 [DOI:10.1038/s44161-023-00419-3]
31. Fang Y-H, Wang SP, Chang H-Y, Yang P-J, Liu P-Y, Liu Y-W. Immunogenicity in stem cell therapy for cardiac regeneration. Acta Cardiologica Sinica. 2020;36(6):588. https://doi.org/ 10.6515/ACS.202011_36(6).20200811A [DOI:10.6515/ACS.202011_36(6).20200811A]
32. Lezmi E, Benvenisty N. The tumorigenic potential of human pluripotent stem cells. Stem Cells Translational Medicine. 2022;11(8):791-6. https://doi.org/ 10.1093/stcltm/szac039 [DOI:10.1093/stcltm/szac039]
33. Venegas-Zamora L, Fiedler M, Perez W, Altamirano F. Bridging the Translational Gap in Heart Failure Research: Using Human iPSC-derived Cardiomyocytes to Accelerate Therapeutic Insights. Methodist DeBakey Cardiovascular Journal. 2023;19(5):5. https://doi.org/ 10.14797/mdcvj.1295 [DOI:10.14797/mdcvj.1295]
34. Raziyeva K, Smagulova A, Kim Y, Smagul S, Nurkesh A, Saparov A. Preconditioned and genetically modified stem cells for myocardial infarction treatment. International journal of molecular sciences. 2020;21(19):7301. https://doi.org/ 10.3390/ijms21197301 [DOI:10.3390/ijms21197301]
35. Gil-Cabrerizo P, Scacchetti I, Garbayo E, Blanco-Prieto MJ. Cardiac tissue engineering for myocardial infarction treatment. European Journal of Pharmaceutical Sciences. 2023;185:106439. https://doi.org/ 10.1016/j.ejps.2023.106439 [DOI:10.1016/j.ejps.2023.106439]
36. Akbar N, Razzaq SS, Salim A, Haneef K. Mesenchymal stem cell-derived exosomes and their MicroRNAs in heart repair and regeneration. Journal of Cardiovascular Translational Research. 2024;17(3):505-22. https://doi.org/ 10.1007/s12265-023-10449-8 [DOI:10.1007/s12265-023-10449-8]
37. Laforest B, Dai W, Tyan L, Lazarevic S, Shen KM, Gadek M, et al. Atrial fibrillation risk loci interact to modulate Ca 2+-dependent atrial rhythm homeostasis. The Journal of clinical investigation. 2019;129(11):4937-50. https://doi.org/ 10.1172/JCI124231 [DOI:10.1172/JCI124231]
38. Tan X, Zhang J, Heng Y, Chen L, Wang Y, Wu S, et al. Locally delivered hydrogels with controlled release of nanoscale exosomes promote cardiac repair after myocardial infarction. Journal of Controlled Release. 2024;368:303-17. https://doi.org/ 10.1016/j.jconrel.2024.02.035 [DOI:10.1016/j.jconrel.2024.02.035]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |